WO2012096436A3 - Lung injury model animal caused by hyperoxia exposure, and kit for diagnosing lung injury caused by hyperoxia exposure using a taz marker - Google Patents

Lung injury model animal caused by hyperoxia exposure, and kit for diagnosing lung injury caused by hyperoxia exposure using a taz marker Download PDF

Info

Publication number
WO2012096436A3
WO2012096436A3 PCT/KR2011/008808 KR2011008808W WO2012096436A3 WO 2012096436 A3 WO2012096436 A3 WO 2012096436A3 KR 2011008808 W KR2011008808 W KR 2011008808W WO 2012096436 A3 WO2012096436 A3 WO 2012096436A3
Authority
WO
WIPO (PCT)
Prior art keywords
taz
caused
mice
hyperoxia
lung injury
Prior art date
Application number
PCT/KR2011/008808
Other languages
French (fr)
Korean (ko)
Other versions
WO2012096436A2 (en
Inventor
황은숙
홍정호
Original Assignee
이화여자대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이화여자대학교 산학협력단 filed Critical 이화여자대학교 산학협력단
Publication of WO2012096436A2 publication Critical patent/WO2012096436A2/en
Publication of WO2012096436A3 publication Critical patent/WO2012096436A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/35—Animals modified by environmental factors, e.g. temperature, O2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Organic Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a lung injury model animal caused by hyperoxia exposure, and a kit for diagnosing lung injury caused by hyperoxia exposure using a TAZ marker. Serous fibroid lung was induced in TAZ-deficient (TAZ-/-) mice, and this was similar to fibroid lung occurring in the lungs of mice in a normal group which were exposed to hyperoxia. TAZ suppresses signal molecules by affecting a signal path related to oxidative stress, enabling the homeostasis of lungs to be controlled. Therefore, TAZ-deficient (TAZ-/-) mice can be usefully used as fibroid lung model mice caused by hyperoxia exposure, and also used for the preparation of fibroid lung model mice caused by hyperoxia exposure, and as screening of candidate substances for treating agents using the mice. Further, the TAZ-deficient (TAZ-/-) mice can be used for diagnosing fibroid lung caused by hyperoxia exposure and a diagnosis kit therefor, by confirming the expression of TAZ gene or protein.
PCT/KR2011/008808 2011-01-13 2011-11-17 Lung injury model animal caused by hyperoxia exposure, and kit for diagnosing lung injury caused by hyperoxia exposure using a taz marker WO2012096436A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0003666 2011-01-13
KR1020110003666A KR101300777B1 (en) 2011-01-13 2011-01-13 Lung injury model mouse exposed hyperoxia, and a kit for diagnosis of lung injury model mouse exposed hyperoxia using TAZ marker

Publications (2)

Publication Number Publication Date
WO2012096436A2 WO2012096436A2 (en) 2012-07-19
WO2012096436A3 true WO2012096436A3 (en) 2012-09-07

Family

ID=46507526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/008808 WO2012096436A2 (en) 2011-01-13 2011-11-17 Lung injury model animal caused by hyperoxia exposure, and kit for diagnosing lung injury caused by hyperoxia exposure using a taz marker

Country Status (2)

Country Link
KR (1) KR101300777B1 (en)
WO (1) WO2012096436A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102162283B1 (en) * 2017-11-28 2020-10-06 충남대학교 산학협력단 Liver fibrosis mouse model without GOLGA2 gene
KR102162289B1 (en) * 2017-11-28 2020-10-06 충남대학교 산학협력단 Pulmonary fibrosis mouse model without GOLGA2 gene
KR102235072B1 (en) * 2018-04-19 2021-04-02 이화여자대학교 산학협력단 Pharmaceutical composition comprising taz polypeptide for preventing or treating of lung disease and method using the same
WO2019212305A1 (en) * 2018-05-04 2019-11-07 사회복지법인 삼성생명공익재단 Screening method for therapeutic substance for preventing or treating bronchopulmonary dysplasia (bpd)
CN115772539A (en) * 2022-11-17 2023-03-10 南京医科大学 Bilateral lung deficiency mouse model with I-type tracheodysplasia phenotype and construction method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060056948A1 (en) * 2004-08-04 2006-03-16 Agency For Science, Technology And Research Methods
US20100263064A1 (en) * 2003-05-30 2010-10-14 Boucher Jr Richard C Animal model for chronic obstructive pulmonary disease and cystic fibrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100263064A1 (en) * 2003-05-30 2010-10-14 Boucher Jr Richard C Animal model for chronic obstructive pulmonary disease and cystic fibrosis
US20060056948A1 (en) * 2004-08-04 2006-03-16 Agency For Science, Technology And Research Methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAKITA, R. ET AL.: "Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ'", AM. J. PHYSIOL. RENAL PHYSIOL., vol. 294, 2008, pages F542 - F553 *
MITANI, A. ET AL.: "Transcriptional coactivator with PDZ-binding motif is essential for normal alveolarization in mice", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 180, 2009, pages 326 - 338 *

Also Published As

Publication number Publication date
KR20120082271A (en) 2012-07-23
KR101300777B1 (en) 2013-08-29
WO2012096436A2 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
WO2013066764A3 (en) Alzheimer's disease signature markers and methods of use
WO2012096436A3 (en) Lung injury model animal caused by hyperoxia exposure, and kit for diagnosing lung injury caused by hyperoxia exposure using a taz marker
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
ATE554389T1 (en) APEX AS A MARKER FOR LUNG CANCER
WO2014045254A3 (en) Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor
WO2011156734A3 (en) Method of characterizing vascular diseases
CR20110470A (en) PROTEINS OF UNION TO IL-17
WO2011027990A3 (en) Extracellular vesicles derived from gram-positive bacteria, and use thereof
WO2013033609A3 (en) Methods and compositions for the treatment and diagnosis of cancer
EA201101520A1 (en) METHODS OF DIAGNOSTICS OF ONCOLOGICAL DISEASES USING EPIMETABOLIC SWITCHES, MULTIPLE-DIFFERENT INTRACELLULAR MOLECULES OR IMPACT FACTORS
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes
WO2014207049A3 (en) Method for determining protein aggregates using surface-fida
ATE503846T1 (en) METHOD FOR DIAGNOSIS OF OVARIAL CARCINOMA
WO2012102535A3 (en) Composition for detecting proteins containing tyrosine oxide-coupled biomaterial
ES2578477T3 (en) ASC as a marker of chronic obstructive pulmonary disease (COPD)
BR112013021056A2 (en) monoclonal antibody, hybridoma cell line, diagnostic kit, methods for producing a monoclonal antibody and binding agent, purified amino acid sequence binding agent, method for obtaining a coding nucleic acid sequence, antibody molecule encoding isolated nucleic acid, vector, isolated host cell, fusion protein, screening method for the presence of a disease, a condition, methods of diagnosing an individual, prognosis for an individual, and monitoring an individual, and , method for detecting the presence or absence of cervical cancer
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
WO2013009146A3 (en) Marker for diagnosing diabetic retinopathy
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
WO2010000467A8 (en) Asc as a marker for lung cancer
ATE554388T1 (en) METHOD AND IMMUNOABSORBENTS FOR SPECIFIC DETECTION AND ABSORPTION OF CELIAC DISEASE AND DERMATITIS HERPETIFORMIS ASSOCIATED ANTIBODIES
WO2013009143A3 (en) Marker for diagnosing diabetic retinopathy
ES2509567T3 (en) Identification of genetic variation in affected tissues

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11855503

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11855503

Country of ref document: EP

Kind code of ref document: A2